Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

By /

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Scroll to Top